What FDA’s record states
| Field | What FDA’s record states | Source |
|---|---|---|
| Recipient | Prime Vitality, Inc. dba Prime Peptides | FDA letter ↗ |
| Location | Santa Barbara, CA | FDA letter ↗ |
| Letter date | Dec 10, 2024 | FDA letter ↗ |
| Posted by FDA | Dec 17, 2024 | FDA index ↗ |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA letter ↗ |
| Subject | Unapproved New Drugs/Misbranded | FDA letter ↗ |
| MARCS-CMS number | 695156 | FDA letter ↗ |
| GLP-1 drugs named | Semaglutide, Tirzepatide, Retatrutide | FDA letter ↗ |
| Response letter | Not published by FDA | FDA letter ↗ |
| Closeout letter | Not published by FDA | FDA letter ↗ |
“This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://primepeptides.co in October 2024 and has observed that your website offers various products as “peptides” including, “Semaglutide” and “Retatrutide.” We have also reviewed your social media websites at www.facebook.com/primepeptidesco, www.instagram.com/primepeptidesco, and www.youtube.com/@PrimePeptide.”FDA warning letter to Prime Vitality, Inc. dba Prime Peptides, Dec 10, 2024 · read the full letter on fda.gov ↗
What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.
Other GLP-1 letters FDA issued that week
Source
Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters